Why the study?
Do phenolic compounds protect against doxorubicin-induced cardiotoxicity?
Do phenolic compounds protect against doxorubicin-induced cardiotoxicity?
Phenolic compounds may offer a promising adjuvant therapeutic strategy to mitigate doxorubicin-induced cardiotoxicity through various molecular protective mechanisms.
Answers are grounded in this paper and cite their sources.
May support phenolic compounds as doxorubicin adjuvants; hypothesis-generating and requires clinical trials before practice change.
Although doxorubicin (DOX) is among the most widely used anticancer agents, its clinical application is hampered owing to its cardiotoxicity. Adjuvant therapy with an antioxidant has been suggested as a promising strategy to reduce DOX-induced adverse effects. In this context, many phenolic compounds have been reported to protect against DOX-induced cardiotoxicity. The cardioprotective effects of phenolic compounds are exerted via multiple mechanisms including inhibition of reactive oxygen species generation, apoptosis, NF-κB, p53, mitochondrial dysfunction, and DNA damage. In this review, we present a summary of the in vitro, in vivo, and clinical findings on the protective mechanisms of phenolic compounds against DOX-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Razavi-Azarkhiavi et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: